6 February 2025   Oral hearings heard the USPTO side with MSD (Merck) over a term extension for a reissued patent, in a case set to have huge implications for pharma market exclusivity, reports Marisa Woutersen.

Latest Features

Americas
Will this year be defined by a concerted shift towards ‘One Health’? Simon Kiddle and Rebecca Tollervey of Mewburn Ellis explore.
Americas
Key developments for the industry this year include a more pro-patent administration and USPTO changes, say Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler.
Americas
The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg.
Americas
Key similarities and differences between the patent systems, particularly in biotech, offer lessons and opportunities for rightsholders, say Daniela Fasoli of Simões Propriedade Intelectual and Jeffrey Morton of Haynes and Boone.
Asia
Free trade zones in Beijing, Shanghai, Guangdong, and Hainan are designed to attract capital into China’s fast-growing healthcare sectors, says Li Mi of Lusheng.
Americas
Well-drafted contracts and ironclad tech security can save time and money when an ex-employee steals IP ‘like sugar packets in Starbucks’, finds Tom Phillips.
Asia
The Beijing IP court’s decision to revive a key semaglutide patent based on experimental data has far-reaching legal and economic implications, says Jennifer Che of Eagle IP
Asia
Recent updates to China’s patent law provide guidelines on PTA calculations, definitions of delays and challenging decisions, say Audrey Cheung, Yolanda Wang and Jennifer Che of Eagle IP.
All features


More News

30 January 2025   Patent “veteran” joins the firm’s Palo Alto office, bringing more than 25 years’ experience in patent prosecution and litigation.
30 January 2025   Five-strong team to open new location in the spring | Office will be led by experienced litigators and patent specialists bringing pharma, biologics, medical devices, femtech, and technology expertise to Chicago.
29 January 2025   Complex legal battle concerns ‘skinny label’ strategy used by generic drug makers, prompting a $235 million award | Pharma giant looks for enhanced damages due to ‘wilful infringement’, while opponent wants another trial.
28 January 2025   Munich division asks pharma company for clarity on territorial scope | Sanofi took battle with four generic makers over Jevtana to UPC.
28 January 2025   Court cites lack of inventiveness and failure to meet reproducibility standards | Decision part of broader international litigation with mixed rulings | Generics still barred from selling products until early February.
28 January 2025   Firm adds partner to Houston office with expertise in biotechnology and complex patent litigation.
24 January 2025   New recruit brings expertise in developing and prosecuting complex patent portfolios for small molecule drug products | Partner joins from New York law firm Fenwick & West.
More news